+关注
greenyellow
暂无个人介绍
IP属地:未知
26
关注
1
粉丝
0
主题
0
勋章
主贴
热门
greenyellow
2021-08-17
buy the dip
China tech stocks lower as nation issues draft competition rules
greenyellow
2021-08-11
baidu 👍🏻
5 Growth Stocks With 110% to 393% Upside, According to Wall Street
greenyellow
2021-08-11
good read
抱歉,原内容已删除
greenyellow
2021-08-09
insane gain rate
抱歉,原内容已删除
greenyellow
2021-08-06
like
Toplines After Hours US Market on Thursday
greenyellow
2021-08-06
good
Qualcomm tops Magna's bid with $4.6 billion offer for Veoneer
greenyellow
2021-08-06
good
抱歉,原内容已删除
greenyellow
2021-08-05
Chinese EV will still be the dominant player in China
抱歉,原内容已删除
greenyellow
2021-08-04
informative
抱歉,原内容已删除
greenyellow
2021-06-18
good recommendation
抱歉,原内容已删除
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3586352028840306","uuid":"3586352028840306","gmtCreate":1623258977373,"gmtModify":1624026421052,"name":"greenyellow","pinyin":"greenyellow","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":26,"tweetSize":10,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖(非转发)","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.02","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.90%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":833052794,"gmtCreate":1629191586118,"gmtModify":1633686690238,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586352028840306","authorIdStr":"3586352028840306"},"themes":[],"htmlText":"buy the dip","listText":"buy the dip","text":"buy the dip","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/833052794","repostId":"1147138826","repostType":4,"repost":{"id":"1147138826","kind":"news","pubTimestamp":1629179191,"share":"https://ttm.financial/m/news/1147138826?lang=&edition=full","pubTime":"2021-08-17 13:46","market":"hk","language":"en","title":"China tech stocks lower as nation issues draft competition rules","url":"https://stock-news.laohu8.com/highlight/detail?id=1147138826","media":"Bloomberg","summary":"The Hang Seng Tech Index dropped as much as 3%, as China’s market regulator released draft rules ban","content":"<p>The Hang Seng Tech Index dropped as much as 3%, as China’s market regulator released draft rules banning unfair competition among the nation’s online platform operators.</p>\n<p>Baidu Inc. and NetEase Inc. slumped as much as 5% while Tencent Holdings Ltd. and Alibaba Group Holding Ltd. slid more than 4%.</p>\n<p><img src=\"https://static.tigerbbs.com/941afd804b1d8567636a57f81beca1e6\" tg-width=\"1200\" tg-height=\"675\" referrerpolicy=\"no-referrer\"></p>\n<p>The wide-ranging proposals released Tuesday come after the tech-industry ministry launched a campaign last month aimed at rooting out a raft of problematic behavior.</p>\n<p>The draft covers protections for intellectual property and brand reputation as well as a ban against using algorithms or fake reviews to promote goods and services. Alongside expressly prohibited behaviors like forced exclusivity arrangements, companies will also not be permitted to use technical means to interfere with the operations of rival platforms or maliciously render those services incompatible with their own.</p>\n<p>The latter could force giants like Tencent and Alibaba Group Holding Ltd. to dismantle their walled-off ecosystems that had prevented users from accessing one company’s services from the other’s platforms. Alibaba Chief Executive Officer Daniel Zhang earlier this month signaled support for the removal of those barriers, saying that he saw “cross-platform openness and connectivity as a positive trend.”</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China tech stocks lower as nation issues draft competition rules</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina tech stocks lower as nation issues draft competition rules\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-17 13:46 GMT+8 <a href=https://www.bloomberg.com/news/articles/2021-08-17/technology-stocks-fall-as-china-issues-draft-competition-rules?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Hang Seng Tech Index dropped as much as 3%, as China’s market regulator released draft rules banning unfair competition among the nation’s online platform operators.\nBaidu Inc. and NetEase Inc. ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-17/technology-stocks-fall-as-china-issues-draft-competition-rules?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"00700":"腾讯控股","09988":"阿里巴巴-W","09999":"网易-S","HSTECH":"恒生科技指数","09618":"京东集团-SW"},"source_url":"https://www.bloomberg.com/news/articles/2021-08-17/technology-stocks-fall-as-china-issues-draft-competition-rules?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147138826","content_text":"The Hang Seng Tech Index dropped as much as 3%, as China’s market regulator released draft rules banning unfair competition among the nation’s online platform operators.\nBaidu Inc. and NetEase Inc. slumped as much as 5% while Tencent Holdings Ltd. and Alibaba Group Holding Ltd. slid more than 4%.\n\nThe wide-ranging proposals released Tuesday come after the tech-industry ministry launched a campaign last month aimed at rooting out a raft of problematic behavior.\nThe draft covers protections for intellectual property and brand reputation as well as a ban against using algorithms or fake reviews to promote goods and services. Alongside expressly prohibited behaviors like forced exclusivity arrangements, companies will also not be permitted to use technical means to interfere with the operations of rival platforms or maliciously render those services incompatible with their own.\nThe latter could force giants like Tencent and Alibaba Group Holding Ltd. to dismantle their walled-off ecosystems that had prevented users from accessing one company’s services from the other’s platforms. Alibaba Chief Executive Officer Daniel Zhang earlier this month signaled support for the removal of those barriers, saying that he saw “cross-platform openness and connectivity as a positive trend.”","news_type":1,"symbols_score_info":{"00700":0.9,"09618":0.9,"09988":0.9,"09999":0.9,"HSTECH":0.9}},"isVote":1,"tweetType":1,"viewCount":542,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":892598142,"gmtCreate":1628670284686,"gmtModify":1633745236815,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586352028840306","authorIdStr":"3586352028840306"},"themes":[],"htmlText":"baidu 👍🏻","listText":"baidu 👍🏻","text":"baidu 👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/892598142","repostId":"2158475046","repostType":4,"repost":{"id":"2158475046","kind":"highlight","pubTimestamp":1628600400,"share":"https://ttm.financial/m/news/2158475046?lang=&edition=full","pubTime":"2021-08-10 21:00","market":"us","language":"en","title":"5 Growth Stocks With 110% to 393% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2158475046","media":"Motley Fool","summary":"Analysts are calling for significant gains in these fast-paced stocks.","content":"<p>For the past nine months, the stock market has been practically unstoppable. The benchmark <b>S&P 500</b> hasn't undergone a single 5% drop, and it's nearly doubled since hitting its bear-market low on March 23, 2020.</p>\n<p>But despite this record-breaking rally, Wall Street still sees value in a number of high-growth stocks. Based on the highest price target issued by a Wall Street investment bank or analyst, the following five growth stocks are expected to return 110% to as much as 393% to shareholders.</p>\n<h2>Coinbase Global: Implied upside of 152%</h2>\n<p>The first rapidly growing stock with abundant upside, at least according to investment firm D.A. Davidson, is cryptocurrency brokerage and ecosystem <b>Coinbase Global</b> (NASDAQ:COIN). If the lofty $650 price target set by D.A. Davidson comes to fruition, Coinbase would deliver gains of 152% to its shareholders, relative to where it closed this past weekend.</p>\n<p>On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, revenue and profits have soared for Coinbase. Net revenue in the first quarter catapulted to $1.6 billion from $179 million in the year-ago period, with net income of $771 million, up from $32 million. Growing institutional interest in digital currencies like <b>Bitcoin</b> and <b>Ethereum</b>, along with rapidly rising prices for the Big <a href=\"https://laohu8.com/S/TWOA.U\">Two</a> in crypto, drove investors to the platform.</p>\n<p>On the other hand, the Coinbase operating model has virtually no barriers to entry, and its trading fees are at risk of constantly being undercut by other cryptocurrency exchanges. Additionally, instead of thriving off of innovation, Coinbase is effectively held hostage by external interest in Bitcoin and Ethereum and the price performance of the Big <a href=\"https://laohu8.com/S/TWOA\">Two</a> digital currencies. When Bitcoin declined by 80% following its late 2017 peak, Coinbase's revenue was nearly halved.</p>\n<p>Long story short, while sales growth has been impressive, Coinbase isn't charting its own path to success. Its reliance on external factors makes $650 a target that's unlikely to be reached.</p>\n<h2>Cresco Labs: Implied upside of 160%</h2>\n<p>One industry where you'll find no shortage of aggressive price targets is cannabis -- specifically the U.S. pot industry. If the highest price target assigned by Wall Street of nearly $29 for <b>Cresco Labs</b> (OTC:CRLBF) proves accurate, investors in this marijuana stock could enjoy upside of 160%. And unlike Coinbase, this is a price target that I believe can eventually be achieved.</p>\n<p>Like other multistate operators, Cresco is expanding its retail operations organically and via acquisition. In June, it opened its 33rd dispensary nationally, and it holds enough retail licenses in its back pocket to eventually have closer to four dozen operating dispensaries.</p>\n<p>From a retail perspective, Cresco appears to be focusing its efforts on high-dollar states, as well as those that issue licenses on a limited basis (e.g., Illinois, Ohio, and Pennsylvania). The advantage of limited-license states is they're purposefully reining in competition. That means Cresco will have a genuine opportunity to build up its brands in key markets without the fear of being overrun by a multistate operator with deeper pockets.</p>\n<p>Cresco is also the cannabis industry's leading wholesaler of weed. Even though wholesale cannabis produces weaker margins than retail, Cresco Labs has more than enough volume to make up for it. That's because it holds one of only a handful of cannabis distribution licenses in California. This license gives the company access to more than 575 dispensaries throughout the Golden State.</p>\n<h2>Baidu: Implied upside of 141%</h2>\n<p>In spite of a recent crackdown by the Chinese government on a host of tech stocks, Wall Street remains largely undeterred that China-based internet search giant <b>Baidu</b> (NASDAQ:BIDU) will head higher. In fact, based on the high-water analyst price target of nearly $395, Baidu could offer gains of as much as 141%.</p>\n<p>The most obvious catalyst for Baidu is its domestically dominant internet search engine. According to GlobalStats, Baidu has controlled between 66.9% and 79.9% of all internet search share in China over the trailing 12 months. Just as advertisers line up for placement on <b>Alphabet</b>'s leading internet search engine Google, they're willing to pay big bucks to reach internet users in China.</p>\n<p>Beyond the sustainable double-digit sales growth potential of internet search, Baidu is seeing exceptional early returns from its investment in cloud services and artificial intelligence (AI). Though these ancillary operations only accounted for 21% of first-quarter sales, revenue jumped by 70%. What's more, cloud services and AI offer higher margins, relative to marketing revenue. Over time, we should see these ancillary segments really boost Baidu's cash flow generation.</p>\n<p>While I wouldn't count on $395 anytime soon, I do believe $395 is a reasonable future price target for the fast-growing Baidu.</p>\n<h2><a href=\"https://laohu8.com/S/ICPT\">Intercept Pharmaceuticals</a>: Implied upside of 393%</h2>\n<p>If you're looking for a company with make-or-break opportunity, biotech stock <b>Intercept Pharmaceuticals</b> (NASDAQ:ICPT) might be for you. This polarizing small-cap drug developer with a focus on therapies to treat liver diseases has price targets from Wall Street ranging from as low as $16 to as high as $82. If this upper target comes to fruition, shareholders would nearly quintuple their money.</p>\n<p>The promise and peril for Intercept lies with obeticholic acid (OCA), an experimental treatment for nonalcoholic steatohepatitis (NASH), which affects between 2% and 5% of adults in this country and has no cure. In one respect, OCA met one of its two co-primary endpoints in the phase 3 Regenerate study -- a statistically significant improvement in fibrosis without a worsening of NASH. However, the highest and most-effective dose also led to a large number of cases of pruritus (itching) in trial participants.</p>\n<p>Ultimately, Intercept's top drug candidate received a Complete Response Letter from the Food and Drug Administration. The plan for Intercept is to provide additional safety and trial data, with the goal of resubmitting the application. Even if OCA is approved and targeted at a small subset of the sickest patients, it could offer blockbuster sales potential in this untapped indication.</p>\n<p>The other consideration here is Ocaliva (the brand-name version of OCA) is already approved to treat primary biliary cholangitis and is on track to bring in $325 million to $340 million in sales this year. With an existing safety profile and a modestly growing sales floor, Intercept's risk/reward ratio looks favorable.</p>\n<p><img src=\"https://static.tigerbbs.com/96d1687ba107475c062f0147fa401ff2\" tg-width=\"700\" tg-height=\"375\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.</p>\n<h2>Nio: Implied upside of 110%</h2>\n<p>A fifth and final growth stock with serious upside, according to Wall Street, is China-based electric vehicle (EV) manufacturer <b>Nio</b> (NYSE:NIO). If the loftiest price target of more than $92 were to come true, investors would see their shares more than double in value.</p>\n<p>The excitement surrounding Nio has to do with the impending electrification of China's automobiles. The Society of Automotive Engineers of China predicted back in 2018 that half of all vehicles sold in the world's largest auto market would run on alternative energy by 2035. With the EV industry predominantly nascent in China, the door is wide open for multiple companies to gobble up significant share.</p>\n<p>Having resolved any funding concerns with capital raises, the focus now is on Nio's production expansion. Even facing industrywide chip shortages, Nio still managed to deliver almost 21,900 EVs during the second quarter, which was more than double what it delivered in the year-ago period. Assuming chip supply issues can be resolved somewhat soon, Nio's annual EV run-rate output should climb toward 150,000.</p>\n<p>Additionally, Nio is enticing new buyers with its battery-as-a-service program. Enrolling in this monthly fee-based program can lop thousands of dollars off the initial purchase price of a vehicle, all while improving buyer loyalty for Nio.</p>\n<p>A $92 price target might be a bit much for a company that's produced fewer than 118,000 EVs inception. Nevertheless, its execution of late is commendable.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Growth Stocks With 110% to 393% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Growth Stocks With 110% to 393% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 21:00 GMT+8 <a href=https://www.fool.com/investing/2021/08/10/5-growth-stocks-with-110-to-393-upside-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For the past nine months, the stock market has been practically unstoppable. The benchmark S&P 500 hasn't undergone a single 5% drop, and it's nearly doubled since hitting its bear-market low on March...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/5-growth-stocks-with-110-to-393-upside-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CRLBF":"Cresco Labs Inc.","ICPT":"Intercept Pharmaceuticals","BIDU":"百度","NIO":"蔚来","COIN":"Coinbase Global, Inc."},"source_url":"https://www.fool.com/investing/2021/08/10/5-growth-stocks-with-110-to-393-upside-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158475046","content_text":"For the past nine months, the stock market has been practically unstoppable. The benchmark S&P 500 hasn't undergone a single 5% drop, and it's nearly doubled since hitting its bear-market low on March 23, 2020.\nBut despite this record-breaking rally, Wall Street still sees value in a number of high-growth stocks. Based on the highest price target issued by a Wall Street investment bank or analyst, the following five growth stocks are expected to return 110% to as much as 393% to shareholders.\nCoinbase Global: Implied upside of 152%\nThe first rapidly growing stock with abundant upside, at least according to investment firm D.A. Davidson, is cryptocurrency brokerage and ecosystem Coinbase Global (NASDAQ:COIN). If the lofty $650 price target set by D.A. Davidson comes to fruition, Coinbase would deliver gains of 152% to its shareholders, relative to where it closed this past weekend.\nOn one hand, revenue and profits have soared for Coinbase. Net revenue in the first quarter catapulted to $1.6 billion from $179 million in the year-ago period, with net income of $771 million, up from $32 million. Growing institutional interest in digital currencies like Bitcoin and Ethereum, along with rapidly rising prices for the Big Two in crypto, drove investors to the platform.\nOn the other hand, the Coinbase operating model has virtually no barriers to entry, and its trading fees are at risk of constantly being undercut by other cryptocurrency exchanges. Additionally, instead of thriving off of innovation, Coinbase is effectively held hostage by external interest in Bitcoin and Ethereum and the price performance of the Big Two digital currencies. When Bitcoin declined by 80% following its late 2017 peak, Coinbase's revenue was nearly halved.\nLong story short, while sales growth has been impressive, Coinbase isn't charting its own path to success. Its reliance on external factors makes $650 a target that's unlikely to be reached.\nCresco Labs: Implied upside of 160%\nOne industry where you'll find no shortage of aggressive price targets is cannabis -- specifically the U.S. pot industry. If the highest price target assigned by Wall Street of nearly $29 for Cresco Labs (OTC:CRLBF) proves accurate, investors in this marijuana stock could enjoy upside of 160%. And unlike Coinbase, this is a price target that I believe can eventually be achieved.\nLike other multistate operators, Cresco is expanding its retail operations organically and via acquisition. In June, it opened its 33rd dispensary nationally, and it holds enough retail licenses in its back pocket to eventually have closer to four dozen operating dispensaries.\nFrom a retail perspective, Cresco appears to be focusing its efforts on high-dollar states, as well as those that issue licenses on a limited basis (e.g., Illinois, Ohio, and Pennsylvania). The advantage of limited-license states is they're purposefully reining in competition. That means Cresco will have a genuine opportunity to build up its brands in key markets without the fear of being overrun by a multistate operator with deeper pockets.\nCresco is also the cannabis industry's leading wholesaler of weed. Even though wholesale cannabis produces weaker margins than retail, Cresco Labs has more than enough volume to make up for it. That's because it holds one of only a handful of cannabis distribution licenses in California. This license gives the company access to more than 575 dispensaries throughout the Golden State.\nBaidu: Implied upside of 141%\nIn spite of a recent crackdown by the Chinese government on a host of tech stocks, Wall Street remains largely undeterred that China-based internet search giant Baidu (NASDAQ:BIDU) will head higher. In fact, based on the high-water analyst price target of nearly $395, Baidu could offer gains of as much as 141%.\nThe most obvious catalyst for Baidu is its domestically dominant internet search engine. According to GlobalStats, Baidu has controlled between 66.9% and 79.9% of all internet search share in China over the trailing 12 months. Just as advertisers line up for placement on Alphabet's leading internet search engine Google, they're willing to pay big bucks to reach internet users in China.\nBeyond the sustainable double-digit sales growth potential of internet search, Baidu is seeing exceptional early returns from its investment in cloud services and artificial intelligence (AI). Though these ancillary operations only accounted for 21% of first-quarter sales, revenue jumped by 70%. What's more, cloud services and AI offer higher margins, relative to marketing revenue. Over time, we should see these ancillary segments really boost Baidu's cash flow generation.\nWhile I wouldn't count on $395 anytime soon, I do believe $395 is a reasonable future price target for the fast-growing Baidu.\nIntercept Pharmaceuticals: Implied upside of 393%\nIf you're looking for a company with make-or-break opportunity, biotech stock Intercept Pharmaceuticals (NASDAQ:ICPT) might be for you. This polarizing small-cap drug developer with a focus on therapies to treat liver diseases has price targets from Wall Street ranging from as low as $16 to as high as $82. If this upper target comes to fruition, shareholders would nearly quintuple their money.\nThe promise and peril for Intercept lies with obeticholic acid (OCA), an experimental treatment for nonalcoholic steatohepatitis (NASH), which affects between 2% and 5% of adults in this country and has no cure. In one respect, OCA met one of its two co-primary endpoints in the phase 3 Regenerate study -- a statistically significant improvement in fibrosis without a worsening of NASH. However, the highest and most-effective dose also led to a large number of cases of pruritus (itching) in trial participants.\nUltimately, Intercept's top drug candidate received a Complete Response Letter from the Food and Drug Administration. The plan for Intercept is to provide additional safety and trial data, with the goal of resubmitting the application. Even if OCA is approved and targeted at a small subset of the sickest patients, it could offer blockbuster sales potential in this untapped indication.\nThe other consideration here is Ocaliva (the brand-name version of OCA) is already approved to treat primary biliary cholangitis and is on track to bring in $325 million to $340 million in sales this year. With an existing safety profile and a modestly growing sales floor, Intercept's risk/reward ratio looks favorable.\n\nThe all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.\nNio: Implied upside of 110%\nA fifth and final growth stock with serious upside, according to Wall Street, is China-based electric vehicle (EV) manufacturer Nio (NYSE:NIO). If the loftiest price target of more than $92 were to come true, investors would see their shares more than double in value.\nThe excitement surrounding Nio has to do with the impending electrification of China's automobiles. The Society of Automotive Engineers of China predicted back in 2018 that half of all vehicles sold in the world's largest auto market would run on alternative energy by 2035. With the EV industry predominantly nascent in China, the door is wide open for multiple companies to gobble up significant share.\nHaving resolved any funding concerns with capital raises, the focus now is on Nio's production expansion. Even facing industrywide chip shortages, Nio still managed to deliver almost 21,900 EVs during the second quarter, which was more than double what it delivered in the year-ago period. Assuming chip supply issues can be resolved somewhat soon, Nio's annual EV run-rate output should climb toward 150,000.\nAdditionally, Nio is enticing new buyers with its battery-as-a-service program. Enrolling in this monthly fee-based program can lop thousands of dollars off the initial purchase price of a vehicle, all while improving buyer loyalty for Nio.\nA $92 price target might be a bit much for a company that's produced fewer than 118,000 EVs inception. Nevertheless, its execution of late is commendable.","news_type":1,"symbols_score_info":{"BIDU":0.9,"COIN":0.9,"CRLBF":0.9,"ICPT":0.9,"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":495,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":892047738,"gmtCreate":1628618780924,"gmtModify":1633745692212,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586352028840306","authorIdStr":"3586352028840306"},"themes":[],"htmlText":"good read","listText":"good read","text":"good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/892047738","repostId":"1128779869","repostType":2,"isVote":1,"tweetType":1,"viewCount":419,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":898414772,"gmtCreate":1628517257696,"gmtModify":1633746523340,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586352028840306","authorIdStr":"3586352028840306"},"themes":[],"htmlText":"insane gain rate","listText":"insane gain rate","text":"insane gain rate","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/898414772","repostId":"1135535489","repostType":4,"isVote":1,"tweetType":1,"viewCount":373,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899579803,"gmtCreate":1628208365802,"gmtModify":1633752659705,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586352028840306","authorIdStr":"3586352028840306"},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/899579803","repostId":"2157451943","repostType":4,"repost":{"id":"2157451943","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628205795,"share":"https://ttm.financial/m/news/2157451943?lang=&edition=full","pubTime":"2021-08-06 07:23","market":"us","language":"en","title":"Toplines After Hours US Market on Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2157451943","media":"Tiger Newspress","summary":"U.S. stock index futures were little changed during overnight trading on Thursday, ahead of Friday’s","content":"<p>U.S. stock index futures were little changed during overnight trading on Thursday, ahead of Friday’s highly anticipated jobs report.</p>\n<p>At 7:20 p.m. ET, Dow e-minis were down 32 points, or 0.09%, S&P 500 e-minis were down 3.25 points, or 0.07%, and Nasdaq 100 e-minis were down 5.25 points, or 0.03%.<img src=\"https://static.tigerbbs.com/fa2a1e6921f0962bd65e976709b6688d\" tg-width=\"1125\" tg-height=\"410\" referrerpolicy=\"no-referrer\"></p>\n<h3><b>Stocks making the biggest moves after hours:</b></h3>\n<p><a href=\"https://laohu8.com/S/DRNA\">Dicerna Pharmaceuticals</a> 24% LOWER; announced positive top-line results from the Company’s PHYOX™2 pivotal clinical trial of nedosiran, which is in development as a once-monthly treatment for primary hyperoxaluria (PH), a family of ultra-rare, life-threatening genetic disorders that initially manifest with complications in the kidneys. Nedosiran is Dicerna’s lead GalXC™ RNAi therapeutic candidate and is designed to inhibit the hepatic lactate dehydrogenase (LDH) enzyme – an enzyme that catalyzes the final step in the glyoxylate metabolism pathway that can lead to oxalate overproduction in patients with PH. The PHYOX2 clinical trial included participants with PH subtypes 1 and 2 (PH1 and PH2).</p>\n<p><a href=\"https://laohu8.com/S/GRPN\">Groupon</a> 14.8% HIGHER; reported Q2 EPS of $0.33, $0.36 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $266 million versus the consensus estimate of $242.47 million. Groupon sees FY2021 revenue of $950-990 million, versus the consensus of $998.1 million.</p>\n<p><a href=\"https://laohu8.com/S/ZNGA\">Zynga</a> 15.7% LOWER; reported Q2 EPS of $0.02, which may not compare to the analyst estimate of $0.09. Revenue for the quarter came in at $720 million versus the consensus estimate of $713.01 million. Entered into a definitive agreement toacquireStarLark, developer of the fast-growing and second-largest mobile golf game in the world, Golf Rival, from Betta Games for $525 million in cash and stock.</p>\n<p><a href=\"https://laohu8.com/S/CSOD\">Cornerstone OnDemand</a> 13.2% HIGHER; entered into a definitive agreement to be acquired by Clearlake Capital Group, L.P. (together with certain of its affiliates, Clearlake), a leading private equity firm. Under the terms of the agreement, Clearlake will acquire the outstanding shares of Cornerstone common stock for $57.50 per share in cash. The transaction has an enterprise value of approximately $5.2 billion.</p>\n<p><a href=\"https://laohu8.com/S/RAMP\">LiveRamp Holdings, Inc.</a> 12.2% HIGHER; reported Q1 EPS of $0.09, $0.11 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $119 million versus the consensus estimate of $112.03 million.</p>\n<p><a href=\"https://laohu8.com/S/CVNA\">Carvana Co.</a> 9.5% HIGHER; reported Q2 EPS of $0.26, $0.67 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $3.34 billion versus the consensus estimate of $2.44 billion.</p>\n<p><a href=\"https://laohu8.com/S/SYNA\">Synaptics</a> 7.2% HIGHER; reported Q4 EPS of $2.18, $0.18 better than the analyst estimate of $2.00. Revenue for the quarter came in at $327.8 million versus the consensus estimate of $324.45 million. Synaptics sees Q1 2022 revenue of $355-385 million, versus the consensus of $349.05 million.</p>\n<p><a href=\"https://laohu8.com/S/NVAX\">Novavax</a> 9% LOWER; Delayed Submission for U.S. Vaccine Approval</p>\n<p><a href=\"https://laohu8.com/S/NET\">Cloudflare, Inc.</a> 5.3% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $152.4 million versus the consensus estimate of $146.06 million. Cloudflare sees FY2021 EPS of ($0.11)-($0.12), versus the consensus of ($0.10). Cloudflare sees FY2021 revenue of $629-633 million, versus the consensus of $614.8 million.</p>\n<p><a href=\"https://laohu8.com/S/EXPE\">Expedia</a> 5.2% LOWER; reported Q2 EPS of ($1.13), $0.48 worse than the analyst estimate of ($0.65). Revenue for the quarter came in at $2.11 billion versus the consensus estimate of $2 billion.</p>\n<p><a href=\"https://laohu8.com/S/QDEL\">Quidel</a> 6.9% LOWER; reported Q2 EPS of $0.75, $0.71 worse than the analyst estimate of $1.46. Revenue for the quarter came in at $176.6 million versus the consensus estimate of $194.5 million.</p>\n<p><a href=\"https://laohu8.com/S/SPCE\">Virgin Galactic</a> 5.2% HIGHER; reported Q2 EPS of ($0.39), $0.06 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $570 thousand versus the consensus estimate of $380 thousand. Reopening Sales, with Prices Beginning at $450,000 Per Seat.</p>\n<p><a href=\"https://laohu8.com/S/PLUG\">Plug Power</a> 7.9% HIGHER; reported Q2 EPS of ($0.18), $0.10 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $124.6 million versus the consensus estimate of $114.02 million.</p>\n<p><a href=\"https://laohu8.com/S/Z\">Zillow</a> 1.14% HIGHER; reported Q2 revenue of $1.3 billion versus the consensus estimate of $1.28 billion.</p>\n<p><a href=\"https://laohu8.com/S/OCUL\">Ocular Therapeutix</a> 4.52% LOWER; announced that Regeneron (NASDAQ:REGN) has terminated the option and license agreement collaboration between the companies. The termination became effective August 5, 2021.</p>\n<p><a href=\"https://laohu8.com/S/MNST\">Monster Beverage</a> 1.69% HIGHER; reported Q2 EPS of $0.75, $0.07 better than the analyst estimate of $0.68. Revenue for the quarter came in at $1.46 billion versus the consensus estimate of $1.39 billion.</p>\n<p><a href=\"https://laohu8.com/S/AIG\">American International Group Inc</a> 2.96% HIGHER; reported Q2 EPS of $1.52, $0.35 better than the analyst estimate of $1.17.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines After Hours US Market on Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines After Hours US Market on Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-06 07:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S. stock index futures were little changed during overnight trading on Thursday, ahead of Friday’s highly anticipated jobs report.</p>\n<p>At 7:20 p.m. ET, Dow e-minis were down 32 points, or 0.09%, S&P 500 e-minis were down 3.25 points, or 0.07%, and Nasdaq 100 e-minis were down 5.25 points, or 0.03%.<img src=\"https://static.tigerbbs.com/fa2a1e6921f0962bd65e976709b6688d\" tg-width=\"1125\" tg-height=\"410\" referrerpolicy=\"no-referrer\"></p>\n<h3><b>Stocks making the biggest moves after hours:</b></h3>\n<p><a href=\"https://laohu8.com/S/DRNA\">Dicerna Pharmaceuticals</a> 24% LOWER; announced positive top-line results from the Company’s PHYOX™2 pivotal clinical trial of nedosiran, which is in development as a once-monthly treatment for primary hyperoxaluria (PH), a family of ultra-rare, life-threatening genetic disorders that initially manifest with complications in the kidneys. Nedosiran is Dicerna’s lead GalXC™ RNAi therapeutic candidate and is designed to inhibit the hepatic lactate dehydrogenase (LDH) enzyme – an enzyme that catalyzes the final step in the glyoxylate metabolism pathway that can lead to oxalate overproduction in patients with PH. The PHYOX2 clinical trial included participants with PH subtypes 1 and 2 (PH1 and PH2).</p>\n<p><a href=\"https://laohu8.com/S/GRPN\">Groupon</a> 14.8% HIGHER; reported Q2 EPS of $0.33, $0.36 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $266 million versus the consensus estimate of $242.47 million. Groupon sees FY2021 revenue of $950-990 million, versus the consensus of $998.1 million.</p>\n<p><a href=\"https://laohu8.com/S/ZNGA\">Zynga</a> 15.7% LOWER; reported Q2 EPS of $0.02, which may not compare to the analyst estimate of $0.09. Revenue for the quarter came in at $720 million versus the consensus estimate of $713.01 million. Entered into a definitive agreement toacquireStarLark, developer of the fast-growing and second-largest mobile golf game in the world, Golf Rival, from Betta Games for $525 million in cash and stock.</p>\n<p><a href=\"https://laohu8.com/S/CSOD\">Cornerstone OnDemand</a> 13.2% HIGHER; entered into a definitive agreement to be acquired by Clearlake Capital Group, L.P. (together with certain of its affiliates, Clearlake), a leading private equity firm. Under the terms of the agreement, Clearlake will acquire the outstanding shares of Cornerstone common stock for $57.50 per share in cash. The transaction has an enterprise value of approximately $5.2 billion.</p>\n<p><a href=\"https://laohu8.com/S/RAMP\">LiveRamp Holdings, Inc.</a> 12.2% HIGHER; reported Q1 EPS of $0.09, $0.11 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $119 million versus the consensus estimate of $112.03 million.</p>\n<p><a href=\"https://laohu8.com/S/CVNA\">Carvana Co.</a> 9.5% HIGHER; reported Q2 EPS of $0.26, $0.67 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $3.34 billion versus the consensus estimate of $2.44 billion.</p>\n<p><a href=\"https://laohu8.com/S/SYNA\">Synaptics</a> 7.2% HIGHER; reported Q4 EPS of $2.18, $0.18 better than the analyst estimate of $2.00. Revenue for the quarter came in at $327.8 million versus the consensus estimate of $324.45 million. Synaptics sees Q1 2022 revenue of $355-385 million, versus the consensus of $349.05 million.</p>\n<p><a href=\"https://laohu8.com/S/NVAX\">Novavax</a> 9% LOWER; Delayed Submission for U.S. Vaccine Approval</p>\n<p><a href=\"https://laohu8.com/S/NET\">Cloudflare, Inc.</a> 5.3% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $152.4 million versus the consensus estimate of $146.06 million. Cloudflare sees FY2021 EPS of ($0.11)-($0.12), versus the consensus of ($0.10). Cloudflare sees FY2021 revenue of $629-633 million, versus the consensus of $614.8 million.</p>\n<p><a href=\"https://laohu8.com/S/EXPE\">Expedia</a> 5.2% LOWER; reported Q2 EPS of ($1.13), $0.48 worse than the analyst estimate of ($0.65). Revenue for the quarter came in at $2.11 billion versus the consensus estimate of $2 billion.</p>\n<p><a href=\"https://laohu8.com/S/QDEL\">Quidel</a> 6.9% LOWER; reported Q2 EPS of $0.75, $0.71 worse than the analyst estimate of $1.46. Revenue for the quarter came in at $176.6 million versus the consensus estimate of $194.5 million.</p>\n<p><a href=\"https://laohu8.com/S/SPCE\">Virgin Galactic</a> 5.2% HIGHER; reported Q2 EPS of ($0.39), $0.06 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $570 thousand versus the consensus estimate of $380 thousand. Reopening Sales, with Prices Beginning at $450,000 Per Seat.</p>\n<p><a href=\"https://laohu8.com/S/PLUG\">Plug Power</a> 7.9% HIGHER; reported Q2 EPS of ($0.18), $0.10 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $124.6 million versus the consensus estimate of $114.02 million.</p>\n<p><a href=\"https://laohu8.com/S/Z\">Zillow</a> 1.14% HIGHER; reported Q2 revenue of $1.3 billion versus the consensus estimate of $1.28 billion.</p>\n<p><a href=\"https://laohu8.com/S/OCUL\">Ocular Therapeutix</a> 4.52% LOWER; announced that Regeneron (NASDAQ:REGN) has terminated the option and license agreement collaboration between the companies. The termination became effective August 5, 2021.</p>\n<p><a href=\"https://laohu8.com/S/MNST\">Monster Beverage</a> 1.69% HIGHER; reported Q2 EPS of $0.75, $0.07 better than the analyst estimate of $0.68. Revenue for the quarter came in at $1.46 billion versus the consensus estimate of $1.39 billion.</p>\n<p><a href=\"https://laohu8.com/S/AIG\">American International Group Inc</a> 2.96% HIGHER; reported Q2 EPS of $1.52, $0.35 better than the analyst estimate of $1.17.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GRPN":"GroupOn","DRNA":"Dicerna Pharmaceuticals, Inc.","AIG":"美国国际集团","CSOD":"Cornerstone OnDemand","CVNA":"Carvana Co.","SYNA":"Synaptics Incorporated","RAMP":"LiveRamp Holdings, Inc.","Z":"Zillow","OCUL":"Ocular Therapeutix","ZNGA":"Zynga","NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2157451943","content_text":"U.S. stock index futures were little changed during overnight trading on Thursday, ahead of Friday’s highly anticipated jobs report.\nAt 7:20 p.m. ET, Dow e-minis were down 32 points, or 0.09%, S&P 500 e-minis were down 3.25 points, or 0.07%, and Nasdaq 100 e-minis were down 5.25 points, or 0.03%.\nStocks making the biggest moves after hours:\nDicerna Pharmaceuticals 24% LOWER; announced positive top-line results from the Company’s PHYOX™2 pivotal clinical trial of nedosiran, which is in development as a once-monthly treatment for primary hyperoxaluria (PH), a family of ultra-rare, life-threatening genetic disorders that initially manifest with complications in the kidneys. Nedosiran is Dicerna’s lead GalXC™ RNAi therapeutic candidate and is designed to inhibit the hepatic lactate dehydrogenase (LDH) enzyme – an enzyme that catalyzes the final step in the glyoxylate metabolism pathway that can lead to oxalate overproduction in patients with PH. The PHYOX2 clinical trial included participants with PH subtypes 1 and 2 (PH1 and PH2).\nGroupon 14.8% HIGHER; reported Q2 EPS of $0.33, $0.36 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $266 million versus the consensus estimate of $242.47 million. Groupon sees FY2021 revenue of $950-990 million, versus the consensus of $998.1 million.\nZynga 15.7% LOWER; reported Q2 EPS of $0.02, which may not compare to the analyst estimate of $0.09. Revenue for the quarter came in at $720 million versus the consensus estimate of $713.01 million. Entered into a definitive agreement toacquireStarLark, developer of the fast-growing and second-largest mobile golf game in the world, Golf Rival, from Betta Games for $525 million in cash and stock.\nCornerstone OnDemand 13.2% HIGHER; entered into a definitive agreement to be acquired by Clearlake Capital Group, L.P. (together with certain of its affiliates, Clearlake), a leading private equity firm. Under the terms of the agreement, Clearlake will acquire the outstanding shares of Cornerstone common stock for $57.50 per share in cash. The transaction has an enterprise value of approximately $5.2 billion.\nLiveRamp Holdings, Inc. 12.2% HIGHER; reported Q1 EPS of $0.09, $0.11 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $119 million versus the consensus estimate of $112.03 million.\nCarvana Co. 9.5% HIGHER; reported Q2 EPS of $0.26, $0.67 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $3.34 billion versus the consensus estimate of $2.44 billion.\nSynaptics 7.2% HIGHER; reported Q4 EPS of $2.18, $0.18 better than the analyst estimate of $2.00. Revenue for the quarter came in at $327.8 million versus the consensus estimate of $324.45 million. Synaptics sees Q1 2022 revenue of $355-385 million, versus the consensus of $349.05 million.\nNovavax 9% LOWER; Delayed Submission for U.S. Vaccine Approval\nCloudflare, Inc. 5.3% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $152.4 million versus the consensus estimate of $146.06 million. Cloudflare sees FY2021 EPS of ($0.11)-($0.12), versus the consensus of ($0.10). Cloudflare sees FY2021 revenue of $629-633 million, versus the consensus of $614.8 million.\nExpedia 5.2% LOWER; reported Q2 EPS of ($1.13), $0.48 worse than the analyst estimate of ($0.65). Revenue for the quarter came in at $2.11 billion versus the consensus estimate of $2 billion.\nQuidel 6.9% LOWER; reported Q2 EPS of $0.75, $0.71 worse than the analyst estimate of $1.46. Revenue for the quarter came in at $176.6 million versus the consensus estimate of $194.5 million.\nVirgin Galactic 5.2% HIGHER; reported Q2 EPS of ($0.39), $0.06 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $570 thousand versus the consensus estimate of $380 thousand. Reopening Sales, with Prices Beginning at $450,000 Per Seat.\nPlug Power 7.9% HIGHER; reported Q2 EPS of ($0.18), $0.10 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $124.6 million versus the consensus estimate of $114.02 million.\nZillow 1.14% HIGHER; reported Q2 revenue of $1.3 billion versus the consensus estimate of $1.28 billion.\nOcular Therapeutix 4.52% LOWER; announced that Regeneron (NASDAQ:REGN) has terminated the option and license agreement collaboration between the companies. The termination became effective August 5, 2021.\nMonster Beverage 1.69% HIGHER; reported Q2 EPS of $0.75, $0.07 better than the analyst estimate of $0.68. Revenue for the quarter came in at $1.46 billion versus the consensus estimate of $1.39 billion.\nAmerican International Group Inc 2.96% HIGHER; reported Q2 EPS of $1.52, $0.35 better than the analyst estimate of $1.17.","news_type":1,"symbols_score_info":{"AIG":0.9,"CSOD":0.9,"CVNA":0.9,"DRNA":0.9,"GRPN":0.9,"NVAX":0.9,"OCUL":0.9,"RAMP":0.9,"SYNA":0.9,"Z":0.9,"ZNGA":0.9}},"isVote":1,"tweetType":1,"viewCount":645,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899675270,"gmtCreate":1628184088890,"gmtModify":1633752827672,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586352028840306","authorIdStr":"3586352028840306"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/899675270","repostId":"2157430168","repostType":4,"repost":{"id":"2157430168","kind":"news","pubTimestamp":1628173962,"share":"https://ttm.financial/m/news/2157430168?lang=&edition=full","pubTime":"2021-08-05 22:32","market":"us","language":"en","title":"Qualcomm tops Magna's bid with $4.6 billion offer for Veoneer","url":"https://stock-news.laohu8.com/highlight/detail?id=2157430168","media":"Reuters","summary":"(Reuters) -Chipmaker Qualcomm Inc said on Thursday it had offered to buy Swedish auto parts maker Ve","content":"<p>(Reuters) -Chipmaker Qualcomm Inc said on Thursday it had offered to buy Swedish auto parts maker Veoneer Inc for $4.6 billion, an 18.4% premium to a bid by Canada's Magna International Inc that was accepted by Veoneer's board.</p>\n<p>U.S.-listed shares of Veoneer rose 21.7% in premarket trading as the stage was set for a bidding war. Neither Magna or Veoneer made any immediate comment.</p>\n<p>Demand has been on the rise for advanced driver assistance systems, known in the industry as ADAS, that add features ranging from collision warning to parking assist. Some systems collect data from cameras and radar to monitor surroundings, interpret the situation and take action.</p>\n<p>Qualcomm, apart from powering mobile phones, has been a chip supplier to carmakers for a decade and last year started its own line of ADAS systems called Snapdragon Ride.</p>\n<p>Earlier this year it signed a signed a collaboration deal with Veoneer to develop a software and chip platform for driver-assistance systems.</p>\n<p>While fully self-driving vehicles are years away, assisted-driving features, such as adaptive cruise control, are being fitted into new cars by most manufacturers.</p>\n<p>Qualcomm hopes to grow its automotive chips business by creating open and competitive platforms for automakers along with Veoneer.</p>\n<p>\"As the automotive industry continues to transform, it is becoming increasingly important for automakers to have a partner who develops horizontal platforms that drive innovation and enable competition,\" said Qualcomm CEO Cristiano Amon.</p>\n<p>Magna has a similar interest in buying Veoneer as it tries to compete with ADAS makers such as Aptiv, Bosch and Continental to capture a larger share of the booming business.</p>\n<p>The Canadian company had offered to buy rival Veoneer in July for about $3.8 billion in cash.</p>\n<p>(Reporting by Chavi Mehta in Bengaluru and Supantha Mukherjee in Stockholm; Editing by Krishna Chandra Eluri, Vinay Dwivedi, Elaine Hardcastle)</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Qualcomm tops Magna's bid with $4.6 billion offer for Veoneer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQualcomm tops Magna's bid with $4.6 billion offer for Veoneer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-05 22:32 GMT+8 <a href=https://finance.yahoo.com/news/qualcomm-offers-buy-automotive-tech-131242676.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) -Chipmaker Qualcomm Inc said on Thursday it had offered to buy Swedish auto parts maker Veoneer Inc for $4.6 billion, an 18.4% premium to a bid by Canada's Magna International Inc that was ...</p>\n\n<a href=\"https://finance.yahoo.com/news/qualcomm-offers-buy-automotive-tech-131242676.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VNE":"Veoneer, Inc.","QCOM":"高通"},"source_url":"https://finance.yahoo.com/news/qualcomm-offers-buy-automotive-tech-131242676.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2157430168","content_text":"(Reuters) -Chipmaker Qualcomm Inc said on Thursday it had offered to buy Swedish auto parts maker Veoneer Inc for $4.6 billion, an 18.4% premium to a bid by Canada's Magna International Inc that was accepted by Veoneer's board.\nU.S.-listed shares of Veoneer rose 21.7% in premarket trading as the stage was set for a bidding war. Neither Magna or Veoneer made any immediate comment.\nDemand has been on the rise for advanced driver assistance systems, known in the industry as ADAS, that add features ranging from collision warning to parking assist. Some systems collect data from cameras and radar to monitor surroundings, interpret the situation and take action.\nQualcomm, apart from powering mobile phones, has been a chip supplier to carmakers for a decade and last year started its own line of ADAS systems called Snapdragon Ride.\nEarlier this year it signed a signed a collaboration deal with Veoneer to develop a software and chip platform for driver-assistance systems.\nWhile fully self-driving vehicles are years away, assisted-driving features, such as adaptive cruise control, are being fitted into new cars by most manufacturers.\nQualcomm hopes to grow its automotive chips business by creating open and competitive platforms for automakers along with Veoneer.\n\"As the automotive industry continues to transform, it is becoming increasingly important for automakers to have a partner who develops horizontal platforms that drive innovation and enable competition,\" said Qualcomm CEO Cristiano Amon.\nMagna has a similar interest in buying Veoneer as it tries to compete with ADAS makers such as Aptiv, Bosch and Continental to capture a larger share of the booming business.\nThe Canadian company had offered to buy rival Veoneer in July for about $3.8 billion in cash.\n(Reporting by Chavi Mehta in Bengaluru and Supantha Mukherjee in Stockholm; Editing by Krishna Chandra Eluri, Vinay Dwivedi, Elaine Hardcastle)","news_type":1,"symbols_score_info":{"QCOM":0.9,"VNE":0.9}},"isVote":1,"tweetType":1,"viewCount":533,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899675116,"gmtCreate":1628184062335,"gmtModify":1633752827915,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586352028840306","authorIdStr":"3586352028840306"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/899675116","repostId":"1173170520","repostType":4,"isVote":1,"tweetType":1,"viewCount":636,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899083119,"gmtCreate":1628142395531,"gmtModify":1631884235730,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586352028840306","authorIdStr":"3586352028840306"},"themes":[],"htmlText":"Chinese EV will still be the dominant player in China","listText":"Chinese EV will still be the dominant player in China","text":"Chinese EV will still be the dominant player in China","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/899083119","repostId":"1169931259","repostType":4,"isVote":1,"tweetType":1,"viewCount":675,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890914494,"gmtCreate":1628075687218,"gmtModify":1633753849739,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586352028840306","authorIdStr":"3586352028840306"},"themes":[],"htmlText":"informative","listText":"informative","text":"informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/890914494","repostId":"1140177077","repostType":4,"isVote":1,"tweetType":1,"viewCount":423,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166787126,"gmtCreate":1624025385065,"gmtModify":1634023921381,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586352028840306","authorIdStr":"3586352028840306"},"themes":[],"htmlText":"good recommendation","listText":"good recommendation","text":"good recommendation","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166787126","repostId":"2144775875","repostType":4,"isVote":1,"tweetType":1,"viewCount":348,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":899579803,"gmtCreate":1628208365802,"gmtModify":1633752659705,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586352028840306","authorIdStr":"3586352028840306"},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/899579803","repostId":"2157451943","repostType":4,"repost":{"id":"2157451943","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628205795,"share":"https://ttm.financial/m/news/2157451943?lang=&edition=full","pubTime":"2021-08-06 07:23","market":"us","language":"en","title":"Toplines After Hours US Market on Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2157451943","media":"Tiger Newspress","summary":"U.S. stock index futures were little changed during overnight trading on Thursday, ahead of Friday’s","content":"<p>U.S. stock index futures were little changed during overnight trading on Thursday, ahead of Friday’s highly anticipated jobs report.</p>\n<p>At 7:20 p.m. ET, Dow e-minis were down 32 points, or 0.09%, S&P 500 e-minis were down 3.25 points, or 0.07%, and Nasdaq 100 e-minis were down 5.25 points, or 0.03%.<img src=\"https://static.tigerbbs.com/fa2a1e6921f0962bd65e976709b6688d\" tg-width=\"1125\" tg-height=\"410\" referrerpolicy=\"no-referrer\"></p>\n<h3><b>Stocks making the biggest moves after hours:</b></h3>\n<p><a href=\"https://laohu8.com/S/DRNA\">Dicerna Pharmaceuticals</a> 24% LOWER; announced positive top-line results from the Company’s PHYOX™2 pivotal clinical trial of nedosiran, which is in development as a once-monthly treatment for primary hyperoxaluria (PH), a family of ultra-rare, life-threatening genetic disorders that initially manifest with complications in the kidneys. Nedosiran is Dicerna’s lead GalXC™ RNAi therapeutic candidate and is designed to inhibit the hepatic lactate dehydrogenase (LDH) enzyme – an enzyme that catalyzes the final step in the glyoxylate metabolism pathway that can lead to oxalate overproduction in patients with PH. The PHYOX2 clinical trial included participants with PH subtypes 1 and 2 (PH1 and PH2).</p>\n<p><a href=\"https://laohu8.com/S/GRPN\">Groupon</a> 14.8% HIGHER; reported Q2 EPS of $0.33, $0.36 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $266 million versus the consensus estimate of $242.47 million. Groupon sees FY2021 revenue of $950-990 million, versus the consensus of $998.1 million.</p>\n<p><a href=\"https://laohu8.com/S/ZNGA\">Zynga</a> 15.7% LOWER; reported Q2 EPS of $0.02, which may not compare to the analyst estimate of $0.09. Revenue for the quarter came in at $720 million versus the consensus estimate of $713.01 million. Entered into a definitive agreement toacquireStarLark, developer of the fast-growing and second-largest mobile golf game in the world, Golf Rival, from Betta Games for $525 million in cash and stock.</p>\n<p><a href=\"https://laohu8.com/S/CSOD\">Cornerstone OnDemand</a> 13.2% HIGHER; entered into a definitive agreement to be acquired by Clearlake Capital Group, L.P. (together with certain of its affiliates, Clearlake), a leading private equity firm. Under the terms of the agreement, Clearlake will acquire the outstanding shares of Cornerstone common stock for $57.50 per share in cash. The transaction has an enterprise value of approximately $5.2 billion.</p>\n<p><a href=\"https://laohu8.com/S/RAMP\">LiveRamp Holdings, Inc.</a> 12.2% HIGHER; reported Q1 EPS of $0.09, $0.11 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $119 million versus the consensus estimate of $112.03 million.</p>\n<p><a href=\"https://laohu8.com/S/CVNA\">Carvana Co.</a> 9.5% HIGHER; reported Q2 EPS of $0.26, $0.67 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $3.34 billion versus the consensus estimate of $2.44 billion.</p>\n<p><a href=\"https://laohu8.com/S/SYNA\">Synaptics</a> 7.2% HIGHER; reported Q4 EPS of $2.18, $0.18 better than the analyst estimate of $2.00. Revenue for the quarter came in at $327.8 million versus the consensus estimate of $324.45 million. Synaptics sees Q1 2022 revenue of $355-385 million, versus the consensus of $349.05 million.</p>\n<p><a href=\"https://laohu8.com/S/NVAX\">Novavax</a> 9% LOWER; Delayed Submission for U.S. Vaccine Approval</p>\n<p><a href=\"https://laohu8.com/S/NET\">Cloudflare, Inc.</a> 5.3% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $152.4 million versus the consensus estimate of $146.06 million. Cloudflare sees FY2021 EPS of ($0.11)-($0.12), versus the consensus of ($0.10). Cloudflare sees FY2021 revenue of $629-633 million, versus the consensus of $614.8 million.</p>\n<p><a href=\"https://laohu8.com/S/EXPE\">Expedia</a> 5.2% LOWER; reported Q2 EPS of ($1.13), $0.48 worse than the analyst estimate of ($0.65). Revenue for the quarter came in at $2.11 billion versus the consensus estimate of $2 billion.</p>\n<p><a href=\"https://laohu8.com/S/QDEL\">Quidel</a> 6.9% LOWER; reported Q2 EPS of $0.75, $0.71 worse than the analyst estimate of $1.46. Revenue for the quarter came in at $176.6 million versus the consensus estimate of $194.5 million.</p>\n<p><a href=\"https://laohu8.com/S/SPCE\">Virgin Galactic</a> 5.2% HIGHER; reported Q2 EPS of ($0.39), $0.06 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $570 thousand versus the consensus estimate of $380 thousand. Reopening Sales, with Prices Beginning at $450,000 Per Seat.</p>\n<p><a href=\"https://laohu8.com/S/PLUG\">Plug Power</a> 7.9% HIGHER; reported Q2 EPS of ($0.18), $0.10 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $124.6 million versus the consensus estimate of $114.02 million.</p>\n<p><a href=\"https://laohu8.com/S/Z\">Zillow</a> 1.14% HIGHER; reported Q2 revenue of $1.3 billion versus the consensus estimate of $1.28 billion.</p>\n<p><a href=\"https://laohu8.com/S/OCUL\">Ocular Therapeutix</a> 4.52% LOWER; announced that Regeneron (NASDAQ:REGN) has terminated the option and license agreement collaboration between the companies. The termination became effective August 5, 2021.</p>\n<p><a href=\"https://laohu8.com/S/MNST\">Monster Beverage</a> 1.69% HIGHER; reported Q2 EPS of $0.75, $0.07 better than the analyst estimate of $0.68. Revenue for the quarter came in at $1.46 billion versus the consensus estimate of $1.39 billion.</p>\n<p><a href=\"https://laohu8.com/S/AIG\">American International Group Inc</a> 2.96% HIGHER; reported Q2 EPS of $1.52, $0.35 better than the analyst estimate of $1.17.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines After Hours US Market on Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines After Hours US Market on Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-06 07:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S. stock index futures were little changed during overnight trading on Thursday, ahead of Friday’s highly anticipated jobs report.</p>\n<p>At 7:20 p.m. ET, Dow e-minis were down 32 points, or 0.09%, S&P 500 e-minis were down 3.25 points, or 0.07%, and Nasdaq 100 e-minis were down 5.25 points, or 0.03%.<img src=\"https://static.tigerbbs.com/fa2a1e6921f0962bd65e976709b6688d\" tg-width=\"1125\" tg-height=\"410\" referrerpolicy=\"no-referrer\"></p>\n<h3><b>Stocks making the biggest moves after hours:</b></h3>\n<p><a href=\"https://laohu8.com/S/DRNA\">Dicerna Pharmaceuticals</a> 24% LOWER; announced positive top-line results from the Company’s PHYOX™2 pivotal clinical trial of nedosiran, which is in development as a once-monthly treatment for primary hyperoxaluria (PH), a family of ultra-rare, life-threatening genetic disorders that initially manifest with complications in the kidneys. Nedosiran is Dicerna’s lead GalXC™ RNAi therapeutic candidate and is designed to inhibit the hepatic lactate dehydrogenase (LDH) enzyme – an enzyme that catalyzes the final step in the glyoxylate metabolism pathway that can lead to oxalate overproduction in patients with PH. The PHYOX2 clinical trial included participants with PH subtypes 1 and 2 (PH1 and PH2).</p>\n<p><a href=\"https://laohu8.com/S/GRPN\">Groupon</a> 14.8% HIGHER; reported Q2 EPS of $0.33, $0.36 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $266 million versus the consensus estimate of $242.47 million. Groupon sees FY2021 revenue of $950-990 million, versus the consensus of $998.1 million.</p>\n<p><a href=\"https://laohu8.com/S/ZNGA\">Zynga</a> 15.7% LOWER; reported Q2 EPS of $0.02, which may not compare to the analyst estimate of $0.09. Revenue for the quarter came in at $720 million versus the consensus estimate of $713.01 million. Entered into a definitive agreement toacquireStarLark, developer of the fast-growing and second-largest mobile golf game in the world, Golf Rival, from Betta Games for $525 million in cash and stock.</p>\n<p><a href=\"https://laohu8.com/S/CSOD\">Cornerstone OnDemand</a> 13.2% HIGHER; entered into a definitive agreement to be acquired by Clearlake Capital Group, L.P. (together with certain of its affiliates, Clearlake), a leading private equity firm. Under the terms of the agreement, Clearlake will acquire the outstanding shares of Cornerstone common stock for $57.50 per share in cash. The transaction has an enterprise value of approximately $5.2 billion.</p>\n<p><a href=\"https://laohu8.com/S/RAMP\">LiveRamp Holdings, Inc.</a> 12.2% HIGHER; reported Q1 EPS of $0.09, $0.11 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $119 million versus the consensus estimate of $112.03 million.</p>\n<p><a href=\"https://laohu8.com/S/CVNA\">Carvana Co.</a> 9.5% HIGHER; reported Q2 EPS of $0.26, $0.67 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $3.34 billion versus the consensus estimate of $2.44 billion.</p>\n<p><a href=\"https://laohu8.com/S/SYNA\">Synaptics</a> 7.2% HIGHER; reported Q4 EPS of $2.18, $0.18 better than the analyst estimate of $2.00. Revenue for the quarter came in at $327.8 million versus the consensus estimate of $324.45 million. Synaptics sees Q1 2022 revenue of $355-385 million, versus the consensus of $349.05 million.</p>\n<p><a href=\"https://laohu8.com/S/NVAX\">Novavax</a> 9% LOWER; Delayed Submission for U.S. Vaccine Approval</p>\n<p><a href=\"https://laohu8.com/S/NET\">Cloudflare, Inc.</a> 5.3% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $152.4 million versus the consensus estimate of $146.06 million. Cloudflare sees FY2021 EPS of ($0.11)-($0.12), versus the consensus of ($0.10). Cloudflare sees FY2021 revenue of $629-633 million, versus the consensus of $614.8 million.</p>\n<p><a href=\"https://laohu8.com/S/EXPE\">Expedia</a> 5.2% LOWER; reported Q2 EPS of ($1.13), $0.48 worse than the analyst estimate of ($0.65). Revenue for the quarter came in at $2.11 billion versus the consensus estimate of $2 billion.</p>\n<p><a href=\"https://laohu8.com/S/QDEL\">Quidel</a> 6.9% LOWER; reported Q2 EPS of $0.75, $0.71 worse than the analyst estimate of $1.46. Revenue for the quarter came in at $176.6 million versus the consensus estimate of $194.5 million.</p>\n<p><a href=\"https://laohu8.com/S/SPCE\">Virgin Galactic</a> 5.2% HIGHER; reported Q2 EPS of ($0.39), $0.06 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $570 thousand versus the consensus estimate of $380 thousand. Reopening Sales, with Prices Beginning at $450,000 Per Seat.</p>\n<p><a href=\"https://laohu8.com/S/PLUG\">Plug Power</a> 7.9% HIGHER; reported Q2 EPS of ($0.18), $0.10 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $124.6 million versus the consensus estimate of $114.02 million.</p>\n<p><a href=\"https://laohu8.com/S/Z\">Zillow</a> 1.14% HIGHER; reported Q2 revenue of $1.3 billion versus the consensus estimate of $1.28 billion.</p>\n<p><a href=\"https://laohu8.com/S/OCUL\">Ocular Therapeutix</a> 4.52% LOWER; announced that Regeneron (NASDAQ:REGN) has terminated the option and license agreement collaboration between the companies. The termination became effective August 5, 2021.</p>\n<p><a href=\"https://laohu8.com/S/MNST\">Monster Beverage</a> 1.69% HIGHER; reported Q2 EPS of $0.75, $0.07 better than the analyst estimate of $0.68. Revenue for the quarter came in at $1.46 billion versus the consensus estimate of $1.39 billion.</p>\n<p><a href=\"https://laohu8.com/S/AIG\">American International Group Inc</a> 2.96% HIGHER; reported Q2 EPS of $1.52, $0.35 better than the analyst estimate of $1.17.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GRPN":"GroupOn","DRNA":"Dicerna Pharmaceuticals, Inc.","AIG":"美国国际集团","CSOD":"Cornerstone OnDemand","CVNA":"Carvana Co.","SYNA":"Synaptics Incorporated","RAMP":"LiveRamp Holdings, Inc.","Z":"Zillow","OCUL":"Ocular Therapeutix","ZNGA":"Zynga","NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2157451943","content_text":"U.S. stock index futures were little changed during overnight trading on Thursday, ahead of Friday’s highly anticipated jobs report.\nAt 7:20 p.m. ET, Dow e-minis were down 32 points, or 0.09%, S&P 500 e-minis were down 3.25 points, or 0.07%, and Nasdaq 100 e-minis were down 5.25 points, or 0.03%.\nStocks making the biggest moves after hours:\nDicerna Pharmaceuticals 24% LOWER; announced positive top-line results from the Company’s PHYOX™2 pivotal clinical trial of nedosiran, which is in development as a once-monthly treatment for primary hyperoxaluria (PH), a family of ultra-rare, life-threatening genetic disorders that initially manifest with complications in the kidneys. Nedosiran is Dicerna’s lead GalXC™ RNAi therapeutic candidate and is designed to inhibit the hepatic lactate dehydrogenase (LDH) enzyme – an enzyme that catalyzes the final step in the glyoxylate metabolism pathway that can lead to oxalate overproduction in patients with PH. The PHYOX2 clinical trial included participants with PH subtypes 1 and 2 (PH1 and PH2).\nGroupon 14.8% HIGHER; reported Q2 EPS of $0.33, $0.36 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $266 million versus the consensus estimate of $242.47 million. Groupon sees FY2021 revenue of $950-990 million, versus the consensus of $998.1 million.\nZynga 15.7% LOWER; reported Q2 EPS of $0.02, which may not compare to the analyst estimate of $0.09. Revenue for the quarter came in at $720 million versus the consensus estimate of $713.01 million. Entered into a definitive agreement toacquireStarLark, developer of the fast-growing and second-largest mobile golf game in the world, Golf Rival, from Betta Games for $525 million in cash and stock.\nCornerstone OnDemand 13.2% HIGHER; entered into a definitive agreement to be acquired by Clearlake Capital Group, L.P. (together with certain of its affiliates, Clearlake), a leading private equity firm. Under the terms of the agreement, Clearlake will acquire the outstanding shares of Cornerstone common stock for $57.50 per share in cash. The transaction has an enterprise value of approximately $5.2 billion.\nLiveRamp Holdings, Inc. 12.2% HIGHER; reported Q1 EPS of $0.09, $0.11 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $119 million versus the consensus estimate of $112.03 million.\nCarvana Co. 9.5% HIGHER; reported Q2 EPS of $0.26, $0.67 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $3.34 billion versus the consensus estimate of $2.44 billion.\nSynaptics 7.2% HIGHER; reported Q4 EPS of $2.18, $0.18 better than the analyst estimate of $2.00. Revenue for the quarter came in at $327.8 million versus the consensus estimate of $324.45 million. Synaptics sees Q1 2022 revenue of $355-385 million, versus the consensus of $349.05 million.\nNovavax 9% LOWER; Delayed Submission for U.S. Vaccine Approval\nCloudflare, Inc. 5.3% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $152.4 million versus the consensus estimate of $146.06 million. Cloudflare sees FY2021 EPS of ($0.11)-($0.12), versus the consensus of ($0.10). Cloudflare sees FY2021 revenue of $629-633 million, versus the consensus of $614.8 million.\nExpedia 5.2% LOWER; reported Q2 EPS of ($1.13), $0.48 worse than the analyst estimate of ($0.65). Revenue for the quarter came in at $2.11 billion versus the consensus estimate of $2 billion.\nQuidel 6.9% LOWER; reported Q2 EPS of $0.75, $0.71 worse than the analyst estimate of $1.46. Revenue for the quarter came in at $176.6 million versus the consensus estimate of $194.5 million.\nVirgin Galactic 5.2% HIGHER; reported Q2 EPS of ($0.39), $0.06 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $570 thousand versus the consensus estimate of $380 thousand. Reopening Sales, with Prices Beginning at $450,000 Per Seat.\nPlug Power 7.9% HIGHER; reported Q2 EPS of ($0.18), $0.10 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $124.6 million versus the consensus estimate of $114.02 million.\nZillow 1.14% HIGHER; reported Q2 revenue of $1.3 billion versus the consensus estimate of $1.28 billion.\nOcular Therapeutix 4.52% LOWER; announced that Regeneron (NASDAQ:REGN) has terminated the option and license agreement collaboration between the companies. The termination became effective August 5, 2021.\nMonster Beverage 1.69% HIGHER; reported Q2 EPS of $0.75, $0.07 better than the analyst estimate of $0.68. Revenue for the quarter came in at $1.46 billion versus the consensus estimate of $1.39 billion.\nAmerican International Group Inc 2.96% HIGHER; reported Q2 EPS of $1.52, $0.35 better than the analyst estimate of $1.17.","news_type":1,"symbols_score_info":{"AIG":0.9,"CSOD":0.9,"CVNA":0.9,"DRNA":0.9,"GRPN":0.9,"NVAX":0.9,"OCUL":0.9,"RAMP":0.9,"SYNA":0.9,"Z":0.9,"ZNGA":0.9}},"isVote":1,"tweetType":1,"viewCount":645,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":892598142,"gmtCreate":1628670284686,"gmtModify":1633745236815,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586352028840306","authorIdStr":"3586352028840306"},"themes":[],"htmlText":"baidu 👍🏻","listText":"baidu 👍🏻","text":"baidu 👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/892598142","repostId":"2158475046","repostType":4,"repost":{"id":"2158475046","kind":"highlight","pubTimestamp":1628600400,"share":"https://ttm.financial/m/news/2158475046?lang=&edition=full","pubTime":"2021-08-10 21:00","market":"us","language":"en","title":"5 Growth Stocks With 110% to 393% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2158475046","media":"Motley Fool","summary":"Analysts are calling for significant gains in these fast-paced stocks.","content":"<p>For the past nine months, the stock market has been practically unstoppable. The benchmark <b>S&P 500</b> hasn't undergone a single 5% drop, and it's nearly doubled since hitting its bear-market low on March 23, 2020.</p>\n<p>But despite this record-breaking rally, Wall Street still sees value in a number of high-growth stocks. Based on the highest price target issued by a Wall Street investment bank or analyst, the following five growth stocks are expected to return 110% to as much as 393% to shareholders.</p>\n<h2>Coinbase Global: Implied upside of 152%</h2>\n<p>The first rapidly growing stock with abundant upside, at least according to investment firm D.A. Davidson, is cryptocurrency brokerage and ecosystem <b>Coinbase Global</b> (NASDAQ:COIN). If the lofty $650 price target set by D.A. Davidson comes to fruition, Coinbase would deliver gains of 152% to its shareholders, relative to where it closed this past weekend.</p>\n<p>On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, revenue and profits have soared for Coinbase. Net revenue in the first quarter catapulted to $1.6 billion from $179 million in the year-ago period, with net income of $771 million, up from $32 million. Growing institutional interest in digital currencies like <b>Bitcoin</b> and <b>Ethereum</b>, along with rapidly rising prices for the Big <a href=\"https://laohu8.com/S/TWOA.U\">Two</a> in crypto, drove investors to the platform.</p>\n<p>On the other hand, the Coinbase operating model has virtually no barriers to entry, and its trading fees are at risk of constantly being undercut by other cryptocurrency exchanges. Additionally, instead of thriving off of innovation, Coinbase is effectively held hostage by external interest in Bitcoin and Ethereum and the price performance of the Big <a href=\"https://laohu8.com/S/TWOA\">Two</a> digital currencies. When Bitcoin declined by 80% following its late 2017 peak, Coinbase's revenue was nearly halved.</p>\n<p>Long story short, while sales growth has been impressive, Coinbase isn't charting its own path to success. Its reliance on external factors makes $650 a target that's unlikely to be reached.</p>\n<h2>Cresco Labs: Implied upside of 160%</h2>\n<p>One industry where you'll find no shortage of aggressive price targets is cannabis -- specifically the U.S. pot industry. If the highest price target assigned by Wall Street of nearly $29 for <b>Cresco Labs</b> (OTC:CRLBF) proves accurate, investors in this marijuana stock could enjoy upside of 160%. And unlike Coinbase, this is a price target that I believe can eventually be achieved.</p>\n<p>Like other multistate operators, Cresco is expanding its retail operations organically and via acquisition. In June, it opened its 33rd dispensary nationally, and it holds enough retail licenses in its back pocket to eventually have closer to four dozen operating dispensaries.</p>\n<p>From a retail perspective, Cresco appears to be focusing its efforts on high-dollar states, as well as those that issue licenses on a limited basis (e.g., Illinois, Ohio, and Pennsylvania). The advantage of limited-license states is they're purposefully reining in competition. That means Cresco will have a genuine opportunity to build up its brands in key markets without the fear of being overrun by a multistate operator with deeper pockets.</p>\n<p>Cresco is also the cannabis industry's leading wholesaler of weed. Even though wholesale cannabis produces weaker margins than retail, Cresco Labs has more than enough volume to make up for it. That's because it holds one of only a handful of cannabis distribution licenses in California. This license gives the company access to more than 575 dispensaries throughout the Golden State.</p>\n<h2>Baidu: Implied upside of 141%</h2>\n<p>In spite of a recent crackdown by the Chinese government on a host of tech stocks, Wall Street remains largely undeterred that China-based internet search giant <b>Baidu</b> (NASDAQ:BIDU) will head higher. In fact, based on the high-water analyst price target of nearly $395, Baidu could offer gains of as much as 141%.</p>\n<p>The most obvious catalyst for Baidu is its domestically dominant internet search engine. According to GlobalStats, Baidu has controlled between 66.9% and 79.9% of all internet search share in China over the trailing 12 months. Just as advertisers line up for placement on <b>Alphabet</b>'s leading internet search engine Google, they're willing to pay big bucks to reach internet users in China.</p>\n<p>Beyond the sustainable double-digit sales growth potential of internet search, Baidu is seeing exceptional early returns from its investment in cloud services and artificial intelligence (AI). Though these ancillary operations only accounted for 21% of first-quarter sales, revenue jumped by 70%. What's more, cloud services and AI offer higher margins, relative to marketing revenue. Over time, we should see these ancillary segments really boost Baidu's cash flow generation.</p>\n<p>While I wouldn't count on $395 anytime soon, I do believe $395 is a reasonable future price target for the fast-growing Baidu.</p>\n<h2><a href=\"https://laohu8.com/S/ICPT\">Intercept Pharmaceuticals</a>: Implied upside of 393%</h2>\n<p>If you're looking for a company with make-or-break opportunity, biotech stock <b>Intercept Pharmaceuticals</b> (NASDAQ:ICPT) might be for you. This polarizing small-cap drug developer with a focus on therapies to treat liver diseases has price targets from Wall Street ranging from as low as $16 to as high as $82. If this upper target comes to fruition, shareholders would nearly quintuple their money.</p>\n<p>The promise and peril for Intercept lies with obeticholic acid (OCA), an experimental treatment for nonalcoholic steatohepatitis (NASH), which affects between 2% and 5% of adults in this country and has no cure. In one respect, OCA met one of its two co-primary endpoints in the phase 3 Regenerate study -- a statistically significant improvement in fibrosis without a worsening of NASH. However, the highest and most-effective dose also led to a large number of cases of pruritus (itching) in trial participants.</p>\n<p>Ultimately, Intercept's top drug candidate received a Complete Response Letter from the Food and Drug Administration. The plan for Intercept is to provide additional safety and trial data, with the goal of resubmitting the application. Even if OCA is approved and targeted at a small subset of the sickest patients, it could offer blockbuster sales potential in this untapped indication.</p>\n<p>The other consideration here is Ocaliva (the brand-name version of OCA) is already approved to treat primary biliary cholangitis and is on track to bring in $325 million to $340 million in sales this year. With an existing safety profile and a modestly growing sales floor, Intercept's risk/reward ratio looks favorable.</p>\n<p><img src=\"https://static.tigerbbs.com/96d1687ba107475c062f0147fa401ff2\" tg-width=\"700\" tg-height=\"375\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.</p>\n<h2>Nio: Implied upside of 110%</h2>\n<p>A fifth and final growth stock with serious upside, according to Wall Street, is China-based electric vehicle (EV) manufacturer <b>Nio</b> (NYSE:NIO). If the loftiest price target of more than $92 were to come true, investors would see their shares more than double in value.</p>\n<p>The excitement surrounding Nio has to do with the impending electrification of China's automobiles. The Society of Automotive Engineers of China predicted back in 2018 that half of all vehicles sold in the world's largest auto market would run on alternative energy by 2035. With the EV industry predominantly nascent in China, the door is wide open for multiple companies to gobble up significant share.</p>\n<p>Having resolved any funding concerns with capital raises, the focus now is on Nio's production expansion. Even facing industrywide chip shortages, Nio still managed to deliver almost 21,900 EVs during the second quarter, which was more than double what it delivered in the year-ago period. Assuming chip supply issues can be resolved somewhat soon, Nio's annual EV run-rate output should climb toward 150,000.</p>\n<p>Additionally, Nio is enticing new buyers with its battery-as-a-service program. Enrolling in this monthly fee-based program can lop thousands of dollars off the initial purchase price of a vehicle, all while improving buyer loyalty for Nio.</p>\n<p>A $92 price target might be a bit much for a company that's produced fewer than 118,000 EVs inception. Nevertheless, its execution of late is commendable.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Growth Stocks With 110% to 393% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Growth Stocks With 110% to 393% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 21:00 GMT+8 <a href=https://www.fool.com/investing/2021/08/10/5-growth-stocks-with-110-to-393-upside-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For the past nine months, the stock market has been practically unstoppable. The benchmark S&P 500 hasn't undergone a single 5% drop, and it's nearly doubled since hitting its bear-market low on March...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/5-growth-stocks-with-110-to-393-upside-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CRLBF":"Cresco Labs Inc.","ICPT":"Intercept Pharmaceuticals","BIDU":"百度","NIO":"蔚来","COIN":"Coinbase Global, Inc."},"source_url":"https://www.fool.com/investing/2021/08/10/5-growth-stocks-with-110-to-393-upside-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158475046","content_text":"For the past nine months, the stock market has been practically unstoppable. The benchmark S&P 500 hasn't undergone a single 5% drop, and it's nearly doubled since hitting its bear-market low on March 23, 2020.\nBut despite this record-breaking rally, Wall Street still sees value in a number of high-growth stocks. Based on the highest price target issued by a Wall Street investment bank or analyst, the following five growth stocks are expected to return 110% to as much as 393% to shareholders.\nCoinbase Global: Implied upside of 152%\nThe first rapidly growing stock with abundant upside, at least according to investment firm D.A. Davidson, is cryptocurrency brokerage and ecosystem Coinbase Global (NASDAQ:COIN). If the lofty $650 price target set by D.A. Davidson comes to fruition, Coinbase would deliver gains of 152% to its shareholders, relative to where it closed this past weekend.\nOn one hand, revenue and profits have soared for Coinbase. Net revenue in the first quarter catapulted to $1.6 billion from $179 million in the year-ago period, with net income of $771 million, up from $32 million. Growing institutional interest in digital currencies like Bitcoin and Ethereum, along with rapidly rising prices for the Big Two in crypto, drove investors to the platform.\nOn the other hand, the Coinbase operating model has virtually no barriers to entry, and its trading fees are at risk of constantly being undercut by other cryptocurrency exchanges. Additionally, instead of thriving off of innovation, Coinbase is effectively held hostage by external interest in Bitcoin and Ethereum and the price performance of the Big Two digital currencies. When Bitcoin declined by 80% following its late 2017 peak, Coinbase's revenue was nearly halved.\nLong story short, while sales growth has been impressive, Coinbase isn't charting its own path to success. Its reliance on external factors makes $650 a target that's unlikely to be reached.\nCresco Labs: Implied upside of 160%\nOne industry where you'll find no shortage of aggressive price targets is cannabis -- specifically the U.S. pot industry. If the highest price target assigned by Wall Street of nearly $29 for Cresco Labs (OTC:CRLBF) proves accurate, investors in this marijuana stock could enjoy upside of 160%. And unlike Coinbase, this is a price target that I believe can eventually be achieved.\nLike other multistate operators, Cresco is expanding its retail operations organically and via acquisition. In June, it opened its 33rd dispensary nationally, and it holds enough retail licenses in its back pocket to eventually have closer to four dozen operating dispensaries.\nFrom a retail perspective, Cresco appears to be focusing its efforts on high-dollar states, as well as those that issue licenses on a limited basis (e.g., Illinois, Ohio, and Pennsylvania). The advantage of limited-license states is they're purposefully reining in competition. That means Cresco will have a genuine opportunity to build up its brands in key markets without the fear of being overrun by a multistate operator with deeper pockets.\nCresco is also the cannabis industry's leading wholesaler of weed. Even though wholesale cannabis produces weaker margins than retail, Cresco Labs has more than enough volume to make up for it. That's because it holds one of only a handful of cannabis distribution licenses in California. This license gives the company access to more than 575 dispensaries throughout the Golden State.\nBaidu: Implied upside of 141%\nIn spite of a recent crackdown by the Chinese government on a host of tech stocks, Wall Street remains largely undeterred that China-based internet search giant Baidu (NASDAQ:BIDU) will head higher. In fact, based on the high-water analyst price target of nearly $395, Baidu could offer gains of as much as 141%.\nThe most obvious catalyst for Baidu is its domestically dominant internet search engine. According to GlobalStats, Baidu has controlled between 66.9% and 79.9% of all internet search share in China over the trailing 12 months. Just as advertisers line up for placement on Alphabet's leading internet search engine Google, they're willing to pay big bucks to reach internet users in China.\nBeyond the sustainable double-digit sales growth potential of internet search, Baidu is seeing exceptional early returns from its investment in cloud services and artificial intelligence (AI). Though these ancillary operations only accounted for 21% of first-quarter sales, revenue jumped by 70%. What's more, cloud services and AI offer higher margins, relative to marketing revenue. Over time, we should see these ancillary segments really boost Baidu's cash flow generation.\nWhile I wouldn't count on $395 anytime soon, I do believe $395 is a reasonable future price target for the fast-growing Baidu.\nIntercept Pharmaceuticals: Implied upside of 393%\nIf you're looking for a company with make-or-break opportunity, biotech stock Intercept Pharmaceuticals (NASDAQ:ICPT) might be for you. This polarizing small-cap drug developer with a focus on therapies to treat liver diseases has price targets from Wall Street ranging from as low as $16 to as high as $82. If this upper target comes to fruition, shareholders would nearly quintuple their money.\nThe promise and peril for Intercept lies with obeticholic acid (OCA), an experimental treatment for nonalcoholic steatohepatitis (NASH), which affects between 2% and 5% of adults in this country and has no cure. In one respect, OCA met one of its two co-primary endpoints in the phase 3 Regenerate study -- a statistically significant improvement in fibrosis without a worsening of NASH. However, the highest and most-effective dose also led to a large number of cases of pruritus (itching) in trial participants.\nUltimately, Intercept's top drug candidate received a Complete Response Letter from the Food and Drug Administration. The plan for Intercept is to provide additional safety and trial data, with the goal of resubmitting the application. Even if OCA is approved and targeted at a small subset of the sickest patients, it could offer blockbuster sales potential in this untapped indication.\nThe other consideration here is Ocaliva (the brand-name version of OCA) is already approved to treat primary biliary cholangitis and is on track to bring in $325 million to $340 million in sales this year. With an existing safety profile and a modestly growing sales floor, Intercept's risk/reward ratio looks favorable.\n\nThe all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.\nNio: Implied upside of 110%\nA fifth and final growth stock with serious upside, according to Wall Street, is China-based electric vehicle (EV) manufacturer Nio (NYSE:NIO). If the loftiest price target of more than $92 were to come true, investors would see their shares more than double in value.\nThe excitement surrounding Nio has to do with the impending electrification of China's automobiles. The Society of Automotive Engineers of China predicted back in 2018 that half of all vehicles sold in the world's largest auto market would run on alternative energy by 2035. With the EV industry predominantly nascent in China, the door is wide open for multiple companies to gobble up significant share.\nHaving resolved any funding concerns with capital raises, the focus now is on Nio's production expansion. Even facing industrywide chip shortages, Nio still managed to deliver almost 21,900 EVs during the second quarter, which was more than double what it delivered in the year-ago period. Assuming chip supply issues can be resolved somewhat soon, Nio's annual EV run-rate output should climb toward 150,000.\nAdditionally, Nio is enticing new buyers with its battery-as-a-service program. Enrolling in this monthly fee-based program can lop thousands of dollars off the initial purchase price of a vehicle, all while improving buyer loyalty for Nio.\nA $92 price target might be a bit much for a company that's produced fewer than 118,000 EVs inception. Nevertheless, its execution of late is commendable.","news_type":1,"symbols_score_info":{"BIDU":0.9,"COIN":0.9,"CRLBF":0.9,"ICPT":0.9,"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":495,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899675270,"gmtCreate":1628184088890,"gmtModify":1633752827672,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586352028840306","authorIdStr":"3586352028840306"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/899675270","repostId":"2157430168","repostType":4,"repost":{"id":"2157430168","kind":"news","pubTimestamp":1628173962,"share":"https://ttm.financial/m/news/2157430168?lang=&edition=full","pubTime":"2021-08-05 22:32","market":"us","language":"en","title":"Qualcomm tops Magna's bid with $4.6 billion offer for Veoneer","url":"https://stock-news.laohu8.com/highlight/detail?id=2157430168","media":"Reuters","summary":"(Reuters) -Chipmaker Qualcomm Inc said on Thursday it had offered to buy Swedish auto parts maker Ve","content":"<p>(Reuters) -Chipmaker Qualcomm Inc said on Thursday it had offered to buy Swedish auto parts maker Veoneer Inc for $4.6 billion, an 18.4% premium to a bid by Canada's Magna International Inc that was accepted by Veoneer's board.</p>\n<p>U.S.-listed shares of Veoneer rose 21.7% in premarket trading as the stage was set for a bidding war. Neither Magna or Veoneer made any immediate comment.</p>\n<p>Demand has been on the rise for advanced driver assistance systems, known in the industry as ADAS, that add features ranging from collision warning to parking assist. Some systems collect data from cameras and radar to monitor surroundings, interpret the situation and take action.</p>\n<p>Qualcomm, apart from powering mobile phones, has been a chip supplier to carmakers for a decade and last year started its own line of ADAS systems called Snapdragon Ride.</p>\n<p>Earlier this year it signed a signed a collaboration deal with Veoneer to develop a software and chip platform for driver-assistance systems.</p>\n<p>While fully self-driving vehicles are years away, assisted-driving features, such as adaptive cruise control, are being fitted into new cars by most manufacturers.</p>\n<p>Qualcomm hopes to grow its automotive chips business by creating open and competitive platforms for automakers along with Veoneer.</p>\n<p>\"As the automotive industry continues to transform, it is becoming increasingly important for automakers to have a partner who develops horizontal platforms that drive innovation and enable competition,\" said Qualcomm CEO Cristiano Amon.</p>\n<p>Magna has a similar interest in buying Veoneer as it tries to compete with ADAS makers such as Aptiv, Bosch and Continental to capture a larger share of the booming business.</p>\n<p>The Canadian company had offered to buy rival Veoneer in July for about $3.8 billion in cash.</p>\n<p>(Reporting by Chavi Mehta in Bengaluru and Supantha Mukherjee in Stockholm; Editing by Krishna Chandra Eluri, Vinay Dwivedi, Elaine Hardcastle)</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Qualcomm tops Magna's bid with $4.6 billion offer for Veoneer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQualcomm tops Magna's bid with $4.6 billion offer for Veoneer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-05 22:32 GMT+8 <a href=https://finance.yahoo.com/news/qualcomm-offers-buy-automotive-tech-131242676.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) -Chipmaker Qualcomm Inc said on Thursday it had offered to buy Swedish auto parts maker Veoneer Inc for $4.6 billion, an 18.4% premium to a bid by Canada's Magna International Inc that was ...</p>\n\n<a href=\"https://finance.yahoo.com/news/qualcomm-offers-buy-automotive-tech-131242676.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VNE":"Veoneer, Inc.","QCOM":"高通"},"source_url":"https://finance.yahoo.com/news/qualcomm-offers-buy-automotive-tech-131242676.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2157430168","content_text":"(Reuters) -Chipmaker Qualcomm Inc said on Thursday it had offered to buy Swedish auto parts maker Veoneer Inc for $4.6 billion, an 18.4% premium to a bid by Canada's Magna International Inc that was accepted by Veoneer's board.\nU.S.-listed shares of Veoneer rose 21.7% in premarket trading as the stage was set for a bidding war. Neither Magna or Veoneer made any immediate comment.\nDemand has been on the rise for advanced driver assistance systems, known in the industry as ADAS, that add features ranging from collision warning to parking assist. Some systems collect data from cameras and radar to monitor surroundings, interpret the situation and take action.\nQualcomm, apart from powering mobile phones, has been a chip supplier to carmakers for a decade and last year started its own line of ADAS systems called Snapdragon Ride.\nEarlier this year it signed a signed a collaboration deal with Veoneer to develop a software and chip platform for driver-assistance systems.\nWhile fully self-driving vehicles are years away, assisted-driving features, such as adaptive cruise control, are being fitted into new cars by most manufacturers.\nQualcomm hopes to grow its automotive chips business by creating open and competitive platforms for automakers along with Veoneer.\n\"As the automotive industry continues to transform, it is becoming increasingly important for automakers to have a partner who develops horizontal platforms that drive innovation and enable competition,\" said Qualcomm CEO Cristiano Amon.\nMagna has a similar interest in buying Veoneer as it tries to compete with ADAS makers such as Aptiv, Bosch and Continental to capture a larger share of the booming business.\nThe Canadian company had offered to buy rival Veoneer in July for about $3.8 billion in cash.\n(Reporting by Chavi Mehta in Bengaluru and Supantha Mukherjee in Stockholm; Editing by Krishna Chandra Eluri, Vinay Dwivedi, Elaine Hardcastle)","news_type":1,"symbols_score_info":{"QCOM":0.9,"VNE":0.9}},"isVote":1,"tweetType":1,"viewCount":533,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890914494,"gmtCreate":1628075687218,"gmtModify":1633753849739,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586352028840306","authorIdStr":"3586352028840306"},"themes":[],"htmlText":"informative","listText":"informative","text":"informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/890914494","repostId":"1140177077","repostType":4,"isVote":1,"tweetType":1,"viewCount":423,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":833052794,"gmtCreate":1629191586118,"gmtModify":1633686690238,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586352028840306","authorIdStr":"3586352028840306"},"themes":[],"htmlText":"buy the dip","listText":"buy the dip","text":"buy the dip","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/833052794","repostId":"1147138826","repostType":4,"repost":{"id":"1147138826","kind":"news","pubTimestamp":1629179191,"share":"https://ttm.financial/m/news/1147138826?lang=&edition=full","pubTime":"2021-08-17 13:46","market":"hk","language":"en","title":"China tech stocks lower as nation issues draft competition rules","url":"https://stock-news.laohu8.com/highlight/detail?id=1147138826","media":"Bloomberg","summary":"The Hang Seng Tech Index dropped as much as 3%, as China’s market regulator released draft rules ban","content":"<p>The Hang Seng Tech Index dropped as much as 3%, as China’s market regulator released draft rules banning unfair competition among the nation’s online platform operators.</p>\n<p>Baidu Inc. and NetEase Inc. slumped as much as 5% while Tencent Holdings Ltd. and Alibaba Group Holding Ltd. slid more than 4%.</p>\n<p><img src=\"https://static.tigerbbs.com/941afd804b1d8567636a57f81beca1e6\" tg-width=\"1200\" tg-height=\"675\" referrerpolicy=\"no-referrer\"></p>\n<p>The wide-ranging proposals released Tuesday come after the tech-industry ministry launched a campaign last month aimed at rooting out a raft of problematic behavior.</p>\n<p>The draft covers protections for intellectual property and brand reputation as well as a ban against using algorithms or fake reviews to promote goods and services. Alongside expressly prohibited behaviors like forced exclusivity arrangements, companies will also not be permitted to use technical means to interfere with the operations of rival platforms or maliciously render those services incompatible with their own.</p>\n<p>The latter could force giants like Tencent and Alibaba Group Holding Ltd. to dismantle their walled-off ecosystems that had prevented users from accessing one company’s services from the other’s platforms. Alibaba Chief Executive Officer Daniel Zhang earlier this month signaled support for the removal of those barriers, saying that he saw “cross-platform openness and connectivity as a positive trend.”</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China tech stocks lower as nation issues draft competition rules</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina tech stocks lower as nation issues draft competition rules\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-17 13:46 GMT+8 <a href=https://www.bloomberg.com/news/articles/2021-08-17/technology-stocks-fall-as-china-issues-draft-competition-rules?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Hang Seng Tech Index dropped as much as 3%, as China’s market regulator released draft rules banning unfair competition among the nation’s online platform operators.\nBaidu Inc. and NetEase Inc. ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-17/technology-stocks-fall-as-china-issues-draft-competition-rules?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"00700":"腾讯控股","09988":"阿里巴巴-W","09999":"网易-S","HSTECH":"恒生科技指数","09618":"京东集团-SW"},"source_url":"https://www.bloomberg.com/news/articles/2021-08-17/technology-stocks-fall-as-china-issues-draft-competition-rules?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147138826","content_text":"The Hang Seng Tech Index dropped as much as 3%, as China’s market regulator released draft rules banning unfair competition among the nation’s online platform operators.\nBaidu Inc. and NetEase Inc. slumped as much as 5% while Tencent Holdings Ltd. and Alibaba Group Holding Ltd. slid more than 4%.\n\nThe wide-ranging proposals released Tuesday come after the tech-industry ministry launched a campaign last month aimed at rooting out a raft of problematic behavior.\nThe draft covers protections for intellectual property and brand reputation as well as a ban against using algorithms or fake reviews to promote goods and services. Alongside expressly prohibited behaviors like forced exclusivity arrangements, companies will also not be permitted to use technical means to interfere with the operations of rival platforms or maliciously render those services incompatible with their own.\nThe latter could force giants like Tencent and Alibaba Group Holding Ltd. to dismantle their walled-off ecosystems that had prevented users from accessing one company’s services from the other’s platforms. Alibaba Chief Executive Officer Daniel Zhang earlier this month signaled support for the removal of those barriers, saying that he saw “cross-platform openness and connectivity as a positive trend.”","news_type":1,"symbols_score_info":{"00700":0.9,"09618":0.9,"09988":0.9,"09999":0.9,"HSTECH":0.9}},"isVote":1,"tweetType":1,"viewCount":542,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":898414772,"gmtCreate":1628517257696,"gmtModify":1633746523340,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586352028840306","authorIdStr":"3586352028840306"},"themes":[],"htmlText":"insane gain rate","listText":"insane gain rate","text":"insane gain rate","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/898414772","repostId":"1135535489","repostType":4,"isVote":1,"tweetType":1,"viewCount":373,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166787126,"gmtCreate":1624025385065,"gmtModify":1634023921381,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586352028840306","authorIdStr":"3586352028840306"},"themes":[],"htmlText":"good recommendation","listText":"good recommendation","text":"good recommendation","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166787126","repostId":"2144775875","repostType":4,"isVote":1,"tweetType":1,"viewCount":348,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899675116,"gmtCreate":1628184062335,"gmtModify":1633752827915,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586352028840306","authorIdStr":"3586352028840306"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/899675116","repostId":"1173170520","repostType":4,"isVote":1,"tweetType":1,"viewCount":636,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899083119,"gmtCreate":1628142395531,"gmtModify":1631884235730,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586352028840306","authorIdStr":"3586352028840306"},"themes":[],"htmlText":"Chinese EV will still be the dominant player in China","listText":"Chinese EV will still be the dominant player in China","text":"Chinese EV will still be the dominant player in China","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/899083119","repostId":"1169931259","repostType":4,"isVote":1,"tweetType":1,"viewCount":675,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":892047738,"gmtCreate":1628618780924,"gmtModify":1633745692212,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586352028840306","authorIdStr":"3586352028840306"},"themes":[],"htmlText":"good read","listText":"good read","text":"good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/892047738","repostId":"1128779869","repostType":2,"isVote":1,"tweetType":1,"viewCount":419,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}